PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Constellation Pharmaceuticals
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Stanford University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fujifilm Pharmaceuticals U.S.A., Inc.
Karyopharm Therapeutics Inc
Stemline Therapeutics, Inc.
Celgene
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
M.D. Anderson Cancer Center
TJ Biopharma Co., Ltd.
University Hospital, Basel, Switzerland
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
OncoVerity, Inc.
Canadian Cancer Trials Group
M.D. Anderson Cancer Center
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
University of Washington
Fate Therapeutics
Memorial Sloan Kettering Cancer Center
Wuerzburg University Hospital
Takeda
H. Lee Moffitt Cancer Center and Research Institute
Gamida Cell ltd
Novartis
Traws Pharma, Inc.
National Cancer Institute (NCI)
Novartis
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Novartis
Duke University
University Health Network, Toronto
Gamida Cell ltd
M.D. Anderson Cancer Center
Novartis
Novartis
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
Regimmune Corporation
Italfarmaco
University of Texas Southwestern Medical Center